Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He recently completed a Master’s degree in communications at Georgetown University.

Latest Posts

Upcoming Webinar: The Future of Partnering

Partnering-HP-Banner

We’ve talked before about the new and improved BIO One-on-One™ partnering system coming for BIO 2015. To give you a sneak peak at the new system, BIO and INOVA are co-hosting a webinar on Thursday, March 19th from 11:00 am – 11:45 am EDT. To RSVP for tomorrow’s webinar, please click here. Find more information about BIO One-on-One Partnering, including upcoming webinars and training events, at convention.bio.org/partner. INOVA and BIO have teamed up to create Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

CDC Report: C. diff Infections Associated with 29,000 Deaths per Year in US; Vaccines Could Provide Solution

MRSA

Last month, the CDC released a new study on the impact of microbial super bug Clostridium difficile (C. diff) with some very disturbing findings. The study found that 29,000 deaths in the U.S. were associated with the bug in 2011, and nearly half a million Americans suffered infections. About half of those deaths, or 15,000, were estimated to be directly attributable to the infection. Elderly patients are most vulnerable to C. diff infections, with over Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO’s Dave Thomas Talks VC Funding with Daniel Levine

72263479

Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, The Bio Report. Dave discussed BIO‘s Venture Funding of Therapeutic Innovation Report, of which he is the lead author. The report analyzes data from four venture capital databases – Thomson Reuters, BioCentury, Elsevier, and Evaluate Pharm – to investigate investor trends, examine investment in specific therapeutic areas and indications, and identify disease areas that might be struggling for early-stage venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

GEN Ranks Top Ten U.S. Biopharma Clusters

BIO International Convention

Yesterday, Alex Philippidis at Genetic Engineering and Biotechnology News released their annual ranking of the top 10 U.S. biopharma clusters. To rank the clusers, five criteria are considered: NIH funding, venture capital funding, number of biotech patents awarded, lab space, and jobs. Landing the number 6 spot is the Greater Philadelphia region, home to this year’s BIO International Convention. From the report: The birthplace of independence saw a nice year-over-year increase in venture capital financing, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Getting Ready for #RDD2015 (Rare Disease Day 2015)

RDD_white

Rare Disease Day is just around the corner on February 28th. R&D investment into rare disease research by venture capitalists was a major focus of BIO’s recent Venture Funding of Therapeutic Innovation between 2004-2013, available for download here. One of the more interesting findings in the study is the large increase of funding by venture capitalists for rare disease R&D over the past decade, as this chart illustrates: Over the last 10 years, there has Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,